Drug · Small Molecule
Hydroxyurea
CI-DRUG-00000671Explore in graph →CHEMBL467 Approved
Regulatory
Approvals (13)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as RIVA-HYDROXYUREA (DIN 02530260) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | May 1, 2023 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as HYDROXYUREA (DIN 02343096) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jul 31, 2017 | Feb 25, 2010 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as APO-HYDROXYUREA (DIN 02247937) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 18 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 8 | 7 | 19 | 64 | 13 | CA, US | Dec 7, 1967 | 1994-10 |
| Leukemia | Phase3 | Phase 3 | 3 | 3 | 9 | 17 | 0 | — | — | 1994-10 |
| Malignant Central Nervous System Neoplasm | Phase3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2004-10 |
| Malignant Laryngeal Neoplasm | Phase3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (65)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06871410 | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07507760 | Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients(DECISIVO) | recruiting |